The Role of Digital Health in Immuno-oncology Therapy Development and Adoption

The FDA is currently overseeing 800 active applications for cell and gene therapies in immuno-oncology (IO), therapies which take advantage of patients’ immune biology to fight cancer. By 2025 they could be approving 10-20 applications each year.

The timing is impeccable, with one-fifth of global pharma sales is spent on oncology, and 40% of US adults will receive a cancer diagnosis in their lifetime. But, it also make treatment decisions more challenging for oncologists: how can a doctor best match patients to appropriate treatments?

In our new white paper, The Role of Digital Health in Immuno-oncology Therapy and Adoption, we explore both the challenges and opportunities that this golden era in cancer treatment is unlocking. 

 Insights from Bristol-Myers Squibb, Cancer Treatment Centers of America, and more

To explore the rapidly evolving immuno-oncology industry and its intersection with digital, BrightInsight spoke with executives from top biopharma companies and oncologists from leading health systems, including:

Download our white paper to learn more about the role that digital is playing in helping to realize and accelerate the impact of IO therapy, including:

We hope it gives you valuable insights into the benefits of doubling down on digital health solutions when developing IO therapies, and shows you how a regulated platform like BrightInsight’s can help you leverage data more efficiently, enable precision medicine, and improve patient access to clinical trials.

Back to Blog